The online hub for digital CME and CE courses
The ONA Forum consultants answer your questions
View articles about patient-focused care
New study results show that partial kidney removal and energy-based techniques to destroy tumors are increasingly used to manage kidney disease. However, the patients most in need of kidney-sparing surgery are surprisingly still more likely to undergo total nephrectomy.
A new immunoassay that tests for the presence of three biomarkers appears to be a valid screening method for the early detection of malignant kidney cancer. The immunoassay measured the levels of three potential biomarkers for kidney cancer.
Levels of three serum proteins are much higher in kidney cancer patients, lending a highly accurate diagnosis.
Animal studies have suggested that sunitinib may promote cancer growth and metastasis, but this does not appear to happen in humans.
A surgical technique known as intracorporeal cooling and extraction (ICE) may reduce the need for conventional open surgery in kidney cancer.
A new radioactive tracer agent can be used with PET/CT to accurately detect clear cell renal cell carcinomas, the most common type of kidney cancer.
Researchers looking at multiple different levels of changes in renal cell carcinoma are closer to determining how these tumors grow and survive.
The mTOR inhibitor dramatically reduced the volume of subependymal giant cell astrocytomas (SEGAs) in persons with tuberous sclerosis complex.
Among patients with renal cell carcinoma, whites consistently have a survival advantage over blacks, regardless of patient or tumor characteristics or surgical treatment. These findings suggest the need for additional efforts to prolong the survival of all patients with kidney cancer.
Active surveillance of small kidney masses is a safe and effective alternative to immediate surgery. The overall and cancer specific survival rates are similar for both approaches.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
| Bone Cancer | Regimens | Drugs |
| Brain Cancer | Regimens | Drugs |
| Breast Cancer | Regimens | Drugs |
| Endocrine Cancer | Regimens | Drugs |
| Gastrointestinal Cancer | Regimens | Drugs |
| Genitourinary Cancer | Regimens | Drugs |
| Gynecologic Cancer | Regimens | Drugs |
| Head and Neck Cancer | Regimens | Drugs |
| Hematologic Cancer | Regimens | Drugs |
| Lung Cancer | Regimens | Drugs |
| Other Cancers | Regimens | |
| Rare Cancers | Regimens | |
| Skin Cancer | Regimens | Drugs |
